By using a chemotherapeutic galvanostat/potentiostat (CGP) likeThe Joey™ from Innovative Potential™, drug molecules work better™ by affording high-presicion surgical control, expanded reactivity and applications, and increased concentration control over pharmaceutical placement outside of a living body.

​

Work better™ is to have external application control over bioactivation.

​

Why do you want a bioactivateable molecule?

Two reasons:

1. EAC prefers bioactivatable molecules because EAC will actually toxify (i.e., activate) a non-toxic molecule to make it pharmacologically effective; and,

2. ​To create molecules with:

• new mechanisms of action,

• lower systemic toxicity,

• lower risk hazard profiles in cases of spills,

• increased transporation safety,

• increased shelf-life, or

• decreased sensitivity to storage conditions.

​​​An ideal EAC drug is:

• a non-toxic prodrug,

• only activated by a CGP, like The Joey™,

• short-lived but stable enough to be pharmacological, and

• can be stored in fluctuating environmental conditions for a long period of time.

​

​​​​These qualities make EAC development ideal for cancer treatments, antibiotics, rural markets, pesticides, harsh environments, explosives, and space travel.

​